Clinical significance of low cytomegalovirus DNA levels in human plasma

Journal of Clinical Microbiology

Volumn 50, Issue 7, 2012, Pages 2378-2383

  Waggoner, Jesse ^a   Ho, Dora Y ^a   Libiran, Paolo ^a   Pinsky, Benjamin A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; VALGANCICLOVIR; VIRUS DNA;

ADULT; ANALYTIC METHOD; ARTICLE; ARTUS CYTOMEGALOVIRUS PROTOCOL; ARTUS CYTOMEGALOVIRUS ROTOR GENE POLYMERASE CHAIN REACTION; BIOASSAY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DNA DETERMINATION; DNA EXTRACTION; FEMALE; GENE DOSAGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AUTOMATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PLASMA; SENSITIVITY AND SPECIFICITY; VIRAL LOAD; VIROLOGY;

EID: 84862726476     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.06800-11     Document Type: Article

References (24)

1. Argene, Inc. 2012. CMV R-gene product information. Argene, Inc., Shirley, NY.
2. Bland JM, Altman DG. 1986. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet i:307-310.
3. Boeckh M, et al. 2004. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J. Clin. Microbiol. 42:1142-1148.
4. Caliendo AM, et al. 2007. Evaluation of real-time PCR laboratory-developed tests using analyte-specific reagents for cytomegalovirus quantification. J. Clin. Microbiol. 45:1723-1727.
5. Caliendo AM, et al. 2000. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients. J. Clin. Microbiol. 38:2122-2127.
6. Chou S. 1992. Effect of interstrain variation on diagnostic DNA amplification of the cytomegalovirus major immediate-early gene region. J. Clin. Microbiol. 30:2307-2310.
7. College of American Pathologists. 2011. VLS-A, viral load participant summary. Surveys and Anatomic Pathology Education Programs, Northfield, IL.
8. Cope AV, et al. 1997. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J. Infect. Dis. 176:1484-1490.
9. Einsele H, et al. 1995. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration of side effects of antiviral therapy after bone marrow transplantation. Blood 86:2815-2820.
10. Emery VC, et al. 2000. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355:2032-2036.
11. Erice A, et al. 2003. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS clinical trials group protocol 360). Clin. Infect. Dis. 37:567-578.
12. Forman M, Wilson A, Valsamakis A. 2011. Cytomegalovirus DNA quantification using an automated platform for nucleic acid extraction and real-time PCR assay setup. J. Clin. Microbiol. 49:2703-2705.
13. Gor D, et al. 1998. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD andCMVdisease. Bone Marrow Transplant. 21:597-605.
14. Humar A, Snydman D, AST Infectious Diseases Community of Practice. 2009. Cytomegalovirus in solid organ transplant recipients. Am. J. Transplant. 9:S78-S86.
15. Kaiser L, et al. 2002. Improved monitoring of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation by an ultrasensitive plasma DNA PCR assay. J. Clin. Microbiol. 40:4251-4255.
16. Lengerova M, et al. 2007. Real-time PCR diagnostics failure caused by nucleotide variability within exon 4 of the human cytomegalovirus major immediate-early gene. J. Clin. Microbiol. 45:1042-1044.
17. Ljungman P, et al. 2008. Management of CMV, HHV-6, HHV-7, and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant. 42:227-240.
18. Ljungman P, et al. 1992. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin. Infect. Dis. 14:831-835.
19. Ljungman P, Griffiths P, Paya C. 2002. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin. Infect. Dis. 34:1094-1097.
20. Meyers JD, Ljungman P, Fisher LD. 1990. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J. Infect. Dis. 162:373-380.
21. National Institute for Biological Standards and Control. 2010. 1st WHO international standard for human cytomegalovirus for nucleic acid amplification techniques. NIBSC code 09/162. South Mimms, Potters Bar, Hertfordshire, England.
22. Raggam RB, et al. 2010. Rapid quantitation of cytomegalovirus DNA in whole blood by a new molecular assay based on automated sample preparation and real-time PCR. Med. Microbiol. Immunol. 199:311-316.
23. Sia IG, et al. 2000. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J. Infect. Dis. 181:717-720.
24. Wolff DJ, LaMarche-Heaney D, Neuwald PD, Stellrecht KA, Press RD. 2009. Multi-site PCR-based CMV viral load assessment-assays demonstrate linearity and precision, but lack numeric standardization. J. Mol. Diagn. 11:87-92.